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Introduction {#sec001}
============

In adult somatic tissues, most cells are differentiated and have specialized roles in maintaining proper tissue and organismal function. During normal turnover or in response to damage, resident adult somatic stem cells can undergo cell division and differentiation, in order to maintain tissue integrity and the proper number of differentiated cells \[[@pgen.1008553.ref001]\]. Characterizing the conserved signaling pathways controlling somatic stem cell activity has been one of the main focus of developmental biology and regenerative medicine. However, studying the process of differentiation *in vivo* remains difficult, as it requires characterizing the successive phenotypical changes associated with cell fate transitions and how signaling pathways and transcriptional networks controls these coordinated cellular changes.

The *Drosophila melanogaster* adult intestine offers a powerful and tractable model to study adult somatic cell differentiation *in vivo*. The intestinal stem cell (ISC) can give rise to the full lineage of cells present in this epithelial tissue. ISC can undergo non-symmetrical cell division and give rise to the progenitors of enteroendocrine cell (EEs) and enterocytes (ECs), pre-EEs and enteroblasts (EBs) respectively. The EB then undergoes growth and terminal differentiation into the large absorptive cell, the enterocyte \[[@pgen.1008553.ref002]--[@pgen.1008553.ref004]\]. In the last decade studies have mostly focused on characterizing the mechanisms that control stem cell proliferation in this tissue. The adult *Drosophila* intestinal epithelium is a very quiescent tissue, where ISC proliferation occurs rarely under homeostasis but is rapidly induced upon tissue damage or infection, via a host of highly conserved signaling pathways \[[@pgen.1008553.ref005]--[@pgen.1008553.ref008]\]. Less is known about signaling pathways controlling ISC and EB differentiation. Studies have shown that the Target of Rapamycin (Tor) signaling pathway is sufficient to induce intestinal progenitor growth and required for differentiation in the EC fate \[[@pgen.1008553.ref009], [@pgen.1008553.ref010]\]. Similarly, Insulin signaling acts cell autonomously in EB regulating its growth and differentiation \[[@pgen.1008553.ref011]\]. Finally, another study has recently suggested that, under stress conditions, EC cell fate is regulated by EGFR signaling in a Tor-independent manner \[[@pgen.1008553.ref012]\].

In parallel to the genetic analysis of the regulator of EB differentiation, recent work has also focused on characterizing the phenotypical transitions associated with EB differentiation and the effect differentiating EB on tissue homeostasis. Antonello et al. showed that EBs can remain undifferentiated, in a dormant-like state, for long periods of time, and that cell death and tissue damage induces EB activation and eventually terminal differentiation into ECs. The activation of dormant EBs is not only coupled with cell growth but also with changes in cell morphology, as EBs gain structures that are actin rich lamellipodia-like, and with formation of thin membrane protrusions. These structures have been hypothesized to mediate activated EB migration to the site of tissue damage before terminal differentiation into ECs \[[@pgen.1008553.ref013]\]. Other studies have highlighted the effect that dormant versus activated EBs have on ISC proliferation. Small dormant EBs inhibit neighboring ISC proliferation via cell/cell contact inhibition, mediated by high levels of E-Cadherin \[[@pgen.1008553.ref011]\], while blocking terminal differentiation of EBs into ECs leads to secretion of mitogens inducing ISC proliferation \[[@pgen.1008553.ref014], [@pgen.1008553.ref015]\]. Despite the progress in our understanding of adult *Drosophila* intestinal progenitor differentiation very little is known of the sequence of events and mechanisms associated with EB activation.

Our work characterizes zfh2, a conserved zinc finger homeodomain transcription factor \[[@pgen.1008553.ref016]\] as a key player in the maintenance of adult intestinal epithelial homeostasis. Zfh2 has previously been studied in the context of *Drosophila* development: during wing development nubbin/Pdm1 represses zfh2 expression, moreover zfh2 expression in this tissue allows Wg activation. Impairing zfh2 expression in this tissue leads to large deletions in the wing hinge and general disorganization of the wing veins \[[@pgen.1008553.ref017], [@pgen.1008553.ref018]\]. In the context of tarsal segment development zfh2 expression is controlled by notch signaling and is required for proper leg size and to form the leg joints between the fourth and the fifth tarsal segment \[[@pgen.1008553.ref019]\]. zfh2 is also expressed in a subset of serotonergic and dopaminergic neurons during larval stage, but its function remains unknown \[[@pgen.1008553.ref020]\]. To date, very little is known about the function of zfh2 in adult tissues, but a recent paper identified a fat body specific role of zfh2 in hypercapnic immune regulation \[[@pgen.1008553.ref021]\]. Interestingly, zfh2 is highly conserved, its mammalian homolog ATBF1 has been proposed as a possible tumor suppressor gene \[[@pgen.1008553.ref022]\]. Altered levels of ATBF1 expression have been correlated with invasiveness and high tumorigenesis in prostate, breast and gastric cancer \[[@pgen.1008553.ref023]--[@pgen.1008553.ref025]\], but the exact mechanism by which ATBF1 may control these processes is not well understood. Another transcription factor has been recently described as another zfh2 homolog: ZFHX4. Mutations in ZFHX4 have been associated with esophageal squamous cell carcinoma migration and invasiveness, but the mechanisms remain unknown \[[@pgen.1008553.ref026], [@pgen.1008553.ref027]\].

In this work we identify zfh2 as a critical player in EB activation and differentiation. We found that zfh2 is expressed in intestinal progenitors, required for EB activation and its over-expression is sufficient to induce cellular phenotypes associated with this process. Our results also establish a hierarchy of genetic requirements and phenotypes associated with EB activation and suggest that the EB needs to be primed by zfh2-dependent mechanisms during activation prior to its growth and differentiation. Finally, we show that zfh2 expression needs to be turned off to allow EB terminal differentiation into ECs. Altogether, our work greatly improves our understanding of the process of EB activation and the role that zfh2 plays in this cellular transition.

Results {#sec002}
=======

zfh2 is expressed in stem cells and enteroblasts in the adult *Drosophila* intestinal epithelium {#sec003}
------------------------------------------------------------------------------------------------

zfh2 expression in the intestinal epithelium and intestinal progenitors has been previously detected by large-scale transcriptomic analyses \[[@pgen.1008553.ref028], [@pgen.1008553.ref029]\]. Before investigating the possible role of zfh2 in the maintenance of intestinal homeostasis, we first confirmed that this protein is expressed in progenitors in the adult gut. Using immunohistochemistry and an antibody directed against zfh2, we detected the zfh2 protein in all escargot-positive (esg+) cells, ISCs and EBs ([Fig 1A](#pgen.1008553.g001){ref-type="fig"}). To confirm the specificity of this staining, we used the temperature sensitive driver esgGal4,UAS-GFP;tubGal80ts (esgGal4ts\>GFP) to express two independent dsRNA constructs against zfh2 and observed that the signal is completely lost ([Fig 1A](#pgen.1008553.g001){ref-type="fig"}). When using specific markers to distinguish between ISCs (Sox21a-positive, Su(H)GBEGal4\>GFP-negative) and EBs (Sox21a-positive, Su(H)GBEGal4\>GFP-positive), we found no difference in zfh2 expression levels between these two cell types under normal conditions or in response to stress ([S1A](#pgen.1008553.s001){ref-type="supplementary-material"}, [S1B and S1C Fig](#pgen.1008553.s001){ref-type="supplementary-material"}). Because Notch signaling is inactive in ISCs and active in EBs \[[@pgen.1008553.ref030]\], this suggests that, unlike during leg development \[[@pgen.1008553.ref019]\], in the intestinal lineage, zfh2 expression is not significantly affected by Notch activity.

![zfh2 is expressed in adult intestinal progenitors.\
(A) Representative confocal images of the posterior midgut. ISCs and EBs are labeled via esgGal4ts\>GFP. zfh2 protein is detected via immunohistochemistry only in GFP-positive cells (indicated by the arrowhead). zfh2 protein is not detected when 2 independent dsRNAs directed against zfh2 are expressed using the esgGal4ts driver. (B) Representative confocal images of the posterior midgut of two zfh2 transcriptional reporters driving GFP expression (zfh2Gal4^GMR73G11^ and Zfh2Gal4^LP30^). βGalactosidase, from the reporter line esgLacZ identifies ISCs and EBs.](pgen.1008553.g001){#pgen.1008553.g001}

To further confirm that zfh2 is exclusively transcribed in ISCs and EBS in the adult intestine, we used two independent transcriptional reporters: Zfh2Gal4^GMR73G11^ (a transgenic construct in which Gal4 is under the control of a 1kb enhancer from the zfh2 locus) and Zfh2Gal4^LP30^ (a Gal4-containing transposon insertion in the zfh2 locus) \[[@pgen.1008553.ref031]\]. We combined these reporters with the esg-LacZ reporter and used immunohistochemistry to label β-galactosidase expressing cells. Both transcriptional reporters are active specifically in all esg+ cells, further confirming that zfh2 is transcriptionally active only in ISCs and EBs in the adult midgut epithelium ([Fig 1B](#pgen.1008553.g001){ref-type="fig"}).

Manipulating zfh2 expression levels specifically affects enteroblast size {#sec004}
-------------------------------------------------------------------------

To investigate the role of zfh2 in the adult intestinal epithelium, we first used temperature sensitive driver esgGal4ts to knock down zfh2 in both ISCs and EBs, using multiple independent dsRNAi constructs. In these conditions, we observed no significant change in the overall composition of the epithelium (i.e. proportion of ISCs, EBs, ECs or EEs) ([S2A Fig](#pgen.1008553.s002){ref-type="supplementary-material"}). However, we found that manipulating zfh2 strongly affects EB cell size. Indeed, we measured cell area of esg+Dl+ ISCs and esg+Dl- EBs and found that knocking-down zfh2 for 3 days weakly affects ISC size but significantly reduces the average size of EBs ([Fig 2A and 2B](#pgen.1008553.g002){ref-type="fig"}). Conversely, over-expressing zfh2, using the UAS-zfh2^EAB^-mCherry insertion line \[[@pgen.1008553.ref018]\] and the esgGal4ts driver, does not affect ISC size but significantly increases EB size ([Fig 2A and 2B](#pgen.1008553.g002){ref-type="fig"}). To test if this effect is cell-autonomous, we repeated the same manipulations with the EB-specific driver Su(H)GBEGal4,tubGal80ts (GBEGal4ts). We found that knocking-down zfh2 in this manner leads to a decrease in the size of EBs, while over-expressing zfh2 leads to an increase in cell size ([Fig 2C and 2D](#pgen.1008553.g002){ref-type="fig"}). Finally, in order to consider possible shape changes induced by manipulating zfh2 that may confound our analysis of cell size based solely on cell area, we directly estimated cell volume by adding the cell area through confocal imaging stacks encompassing entire EBs. Consistent with our previous observations, zfh2 knock-down results in smaller EBs, while zfh2 over-expression significantly increases EB size ([Fig 2D](#pgen.1008553.g002){ref-type="fig"}).

![zfh2 controls enteroblast growth.\
(A) Representative confocal images of the posterior midgut. ISCs and EBs express GFP (esgGal4ts\>GFP). ISCs and enteroendocrine cells are labeled via immunohistochemistry against Delta (red, membrane) and prospero (red, nuclear) respectively. ISCs are identified as GFP-positive, Delta-positive cells (arrowheads) and EBs are identified as GFP-positive, delta-negative cells (asterisks). Inserts show the isolated Delta/Prospero channel of the boxed regions to highlight the difference in Delta staining between ISCs and EBs. zfh2 over-expression, by driving the UAS-zfh2EAB transgene using esgGal4ts, is sufficient to increase EB cell size. zfh2 knock-down, by driving dsRNAs against zfh2, leads to smaller EB size. (B) Cell size of ISCs and EBs is quantified by measuring cell area of individual cells. (C) EBs are specifically labeled by GBEGal4ts\>mCD8GFP expression. zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using GBEGal4ts. zfh2 is knocked-down by driving dsRNA against zfh2 using GBEGal4ts. (D) Cell size of EBs is quantified by measuring cell area of individual cells. Cell volume of EBs is quantified by adding cell areas through entire z-stacks containing EBs. In B and D values are presented as average +/- s.e.m. and p-values are calculated using a two-tailed Student's t-test.](pgen.1008553.g002){#pgen.1008553.g002}

During tissue turnover or regeneration, EB growth is part of the EB differentiation process. Newly formed EBs can remain in a dormant state for an extended period before undergoing growth and endoreplication as part of a process known as EB activation, eventually leading to terminal differentiation into ECs \[[@pgen.1008553.ref013]\]. Dormant EBs are similar in size and shape to its diploid neighboring ISCs. Comparing ISCs and EBs size, we observed that around 50% of wild-type EBs have a cell area comparable to small diploid ISCs, consistent with the high percentage of dormant EBs. However, we found that knocking down zfh2 in EBs increases the number of small EBs (93% and 97% of EBs with sizes similar to wild type ISCs) and, conversely, over-expressing zfh2 leads to an increase in the number of EBs larger than ISCs (from 47% in the control to 73% after zfh2 over-expression) ([Fig 2A and 2B](#pgen.1008553.g002){ref-type="fig"}). During the process of EB activation and differentiation, EB growth is coupled with endoreplication. In the same zfh2 knock-down conditions, we observed an accumulation of EBs with small nuclei, identical in size to diploid ISCs, supporting the notion that zfh2 is required for EB endoreplication ([S2B and S2C Fig](#pgen.1008553.s002){ref-type="supplementary-material"}).

Altogether these data strongly suggest that zfh2 is required and sufficient for EB activation.

Characterization of the enteroblast activation and the role of zfh2 {#sec005}
-------------------------------------------------------------------

The morphological and transcriptional changes associated with EB activation have recently started to be described \[[@pgen.1008553.ref013]\]. However, no rigorous method to quantify the activation state of EBs have been established. Therefore, to investigate the role of zfh2 specifically in the activation process, we first established ways to measure and quantify the activation state of EBs. Dormant EBs have been described as similar to ISC in their oval-like morphology. Upon activation, EBs take a more elongated and irregular shape, with the formation of pseudopodia and thin membrane protrusions that can only be observed in non-fixed tissue \[[@pgen.1008553.ref013]\]. We first used DSS (Dextran Sulfate Sodium), a chemical stressor that acts by disorganizing the basement membrane \[[@pgen.1008553.ref005]\], to induce synchronous and rapid activation of the majority of EBs in the epithelium. When we imaged EBs expressing membrane-bound GFP without fixation, we observed an increase in the presence of EBs with irregular shapes and thin membrane protrusions 6 hours after DSS treatment ([Fig 3A](#pgen.1008553.g003){ref-type="fig"}). These protrusions are not present after a 12hour treatment, suggesting that these morphological changes are transient and associated with early EB activation ([Fig 3A](#pgen.1008553.g003){ref-type="fig"}). To quantitatively characterize the activation state of EBs, we measured cell circularity and categorized EBs based on the presence of membrane protrusions, and confirmed that EBs are activated (low circularity and high number of protrusions) in the intestine of flies fed DSS for 6 hours ([Fig 3B and 3C](#pgen.1008553.g003){ref-type="fig"}). Next, we asked whether similar EB activation can be detected in response to other stimuli and found that the same EB morphological changes can be detected 3 to 4 hours after infection with the bacterium Ecc15 or exposure to oxidative stressor paraquat ([S3A](#pgen.1008553.s003){ref-type="supplementary-material"}, [S3B and S3C Fig](#pgen.1008553.s003){ref-type="supplementary-material"}). Finally, we confirmed that the detected membrane protrusions are actin-rich, as previously reported \[[@pgen.1008553.ref013]\], using the moesin-GFP reporter ([S3D Fig](#pgen.1008553.s003){ref-type="supplementary-material"}).

![zfh2 regulates enteroblast activation.\
(A, D and G) Representative confocal images of non-fixed posterior midgut epithelia. EBs are labeled by GBEGal4ts\>mCD8GFP. Note that autofluorescence signal from trachea is also visible in some images. (A) Stress mediated EB activation is induced by DSS exposure for either 6 or 12h. Morphological and size changes are apparent in EBs 6 hours after treatment. (B) Changes in cell morphology 6 hours after stress induction are quantified by measuring circularity of individual cells. (C) Presence or absence of thin membrane protrusions are quantified in individual cells 6h after DSS mediated stress. Categories are defined as: Type 1 cells have none to few membrane protrusions (\<10), type 2 cells have many (\>10) thin membrane protrusions, type 3 cells have many long and thick membrane protrusions (\>2.5 μm in length). 6 hours of DSS treatment are sufficient to induce an increase in the percentage of cells with membrane protrusions. (D) zfh2 is knocked-down by driving dsRNAs against zfh2 using GBEGal4ts. zfh2 knock-down is sufficient to block DSS-induced changes in cell morphology (E) and the increase in cells with thin membrane protrusions (F). (G) zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using GBEGal4ts. zfh2 over-expression is sufficient to decrease circularity (H) and increase the number of EBs with membrane protrusions (I). In B, E and H values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test. In C, F an I p-values are calculated using the Mann-Whitney test.](pgen.1008553.g003){#pgen.1008553.g003}

Using this methodology, we next assessed the effect of manipulating zfh2 expression in EB activation. Using the GBEGal4ts driver to express two zfh2RNAi construct, we found that knocking-down zfh2 prevents DSS-induced EB activation as shown by the high circularity and absence of protrusion in GBEGal4ts\>zfh2RNAi EBs ([Fig 3D, 3E and 3F](#pgen.1008553.g003){ref-type="fig"}). Conversely, over-expressing zfh2 under normal culture conditions is sufficient to decrease EB circularity and induced the formation of cellular protrusions ([Fig 3G, 3H and 3I](#pgen.1008553.g003){ref-type="fig"}). Besides changes in morphology, activated EBs have been shown to express high levels of the transcription factor Sox21a \[[@pgen.1008553.ref014], [@pgen.1008553.ref015], [@pgen.1008553.ref032]\]. To confirm that zfh2 regulates activation, we investigated the expression of Sox21a in zfh2 gain-of-function and found that over-expressing zfh2 is sufficient to induce Sox21a expression in EBs ([S3E and S3F Fig](#pgen.1008553.s003){ref-type="supplementary-material"}).

Together, our results demonstrate that zfh2 expression in EBs is required for their activation and that increased zfh2 expression is sufficient promote EB activation.

Influence of zfh2-mediated enteroblast activation on tissue homeostasis {#sec006}
-----------------------------------------------------------------------

EB activation is required prior to EB differentiation into ECs. Therefore, we predicted that zfh2 is also required for terminal differentiation. To test this notion, we used the G-TRACE expression system \[[@pgen.1008553.ref033]\] to permanently label and knock-down zfh2 in EB lineages and immunostaining against the transcription factor Pdm1 as a marker of terminal differentiation. In absence of stress, we identified a limited number of newly differentiated ECs within a 6 days period after labeling induction ([Fig 4A](#pgen.1008553.g004){ref-type="fig"}). However, after DSS treatment in control animals, we detected an increase in newly differentiated Pdm1+ ECs, allowing us to measure a significant differentiation index (number of ECs normalized by the number of EBs). When zfh2RNAi is expressed in EBs, no significant differentiation was measured after stress exposure, confirming that zfh2-dependent EB activation is required prior to differentiation ([Fig 4A](#pgen.1008553.g004){ref-type="fig"}).

![zfh2 is essential to maintain intestinal homeostasis.\
(A) The G-TRACE lineage tracing reporter is driven by the GBEGal4ts to permanently label EBs with GFP. ECs are labeled by immunohistochemistry against Pdm1. Flies are treated with DSS for 24 hours to induce EB activation and then left to recover under normal conditions for 48 hours. EBs are identified as small GFP-positive Pdm1-negative cells (asterisk), while newly differentiated EC are large GFP-positive Pdm1-positive cells (arrowhead). Differentiation ratio is measured as the ratio between newly differentiated EC (GFP+ PDM1+ cells) and EB (GFP+ PDM1- cells) in the posterior midgut. Each value represents the average of 2 ROI per midgut. Knocking-down zfh2 by driving dsRNA blocks terminal differentiation of EB into EC. (B) zfh2 is knocked-down in EBs by driving dsRNA using GBEGal4ts. Flies were fed either DSS or Sucrose for 48 hours before dissection and fixation. Mitoses per gut are measured using immunohistochemistry against phospho-Histone H3. zfh2 knock-down in EBs impairs DSS-mediated ISC proliferation non-cell autonomously. (C) zfh2 is over-expressed in EBs by driving the UAS-zfh2EAB transgene, using GBEGal4ts, or in ISCs using the DlGal4ts or esgGal4ts,GBEGal80 drivers. zfh2 is sufficient to promote ISC proliferation non-cell autonomously. In A, B and C values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test.](pgen.1008553.g004){#pgen.1008553.g004}

In addition to differentiation, the activation state of EBs also affects ISC proliferation in a non-cell autonomous manner. Small dormant EBs inhibit neighboring ISC proliferation via cell/cell contact interaction mediated by high levels of the adhesion protein, E-Cadherin \[[@pgen.1008553.ref011]\]. Conversely, blocking EB terminal differentiation into EC, and thus likely arresting EBs in an activated state, induces ISC proliferation via the JAK/STAT and EGFR signaling \[[@pgen.1008553.ref015], [@pgen.1008553.ref032]\]. Consistent with the notion that knocking-down zfh2 arrests EBs in a dormant state, we observed that expressing zfh2RNAi in an EB-specific manner is sufficient to partially impair ISC proliferation induced by DSS ([Fig 4B](#pgen.1008553.g004){ref-type="fig"}). On the contrary, promoting EB activation by over-expression of zfh2 specifically in EBs (GBEGal4ts driver) induces ISC proliferation, while over-expression in ISCs (DlGal4ts and ISCGal4ts) has no effect ([Fig 4C](#pgen.1008553.g004){ref-type="fig"}).

These analyses of differentiation and proliferation further demonstrate that zfh2 significantly impact tissue homeostasis in the intestinal epithelium by regulating EB activation.

zfh2-mediated activation is required for cell growth in enteroblasts {#sec007}
--------------------------------------------------------------------

We found that zfh2 controls EB activation and growth. Thus, we asked whether promoting growth is sufficient to induce activation or rather whether zfh2-dependent EB activation is required for cell growth. Several signaling pathways have been implicated in EB growth and terminal differentiation, including Tor, insulin and Ras signaling \[[@pgen.1008553.ref009]--[@pgen.1008553.ref012]\]. The function of the Tor pathway in EB growth is best characterized. Thus, we first asked whether zfh2 in EBs can induce Tor activity. To this end, we measured Tor activity by quantifying protein levels of the downstream target of the Tor kinase complex 1 (Torc1), phospho-4EBP (p4EBP). We found that over-expressing zfh2 in EBs using the Su(H)GBEGal4ts driver is sufficient to detect increased p4EBP levels by immunostaining ([Fig 5A](#pgen.1008553.g005){ref-type="fig"}). Similar induction was also detected in ISCs and EBs when UAS-zfh2EAB expression was driven by the esgGal4ts driver ([S4A Fig](#pgen.1008553.s004){ref-type="supplementary-material"}). Over-expression of Tor activator Rheb or knock-down of Thor/4-EBP confirmed the specificity of the p4EBP signal (Figs [5A](#pgen.1008553.g005){ref-type="fig"}, [S4A and S4B](#pgen.1008553.s004){ref-type="supplementary-material"}).

![zfh2-mediated activation is required for cell growth in enteroblasts.\
(A) zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using GBEGal4ts. 4EBP (Thor) is knocked-down in EBs by driving dsRNA using GBEGal4ts. EBs are labeled by GBEGal4ts\> mCD8GFP and p4EBP is labeled via immunohistochemistry. p4EBP is detected in EBs (GFP positive cells) and in some small GFP negative cells (arrowhead and asterisk respectively). Protein levels are quantified by measuring mean fluorescence intensity of individual EBs. Inducing EB activation via zfh2 over-expression is sufficient to increase Tor signaling activity. (B) zfh2 is over-expressed by driving the zfh2EAB transgene using GBEGal4ts, Tor activity is inhibited via Rapamycin or by co-expression of the TSC1+2 complex. EBs are labeled by GBEGal4ts\> mCD8GFP.Cell size of EB are quantified by measuring cell area of individual cells. Tor signaling is required for zfh2 mediated EB growth. (C) zfh2 is knocked-down in EB by driving dsRNA against zfh2 using GBEGal4ts, Tor activity is stimulated by over-expression of the Tor activator Rheb. Cell size of EB is quantified by measuring cell area of individual cells. Stimulation of Tor activity is sufficient to induce EB growth in a zfh2 dependent manner. Driving EB Growth via over-expression of the Tor activator Rheb is not sufficient to induce changes in cell morphology, measured by cell circularity (D), formation of membrane protrusions (E) or to induce ISC proliferation non-cell autonomously (F). In A, B, C, D, F, values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test. In E p-values are calculated using the Mann-Whitney test.](pgen.1008553.g005){#pgen.1008553.g005}

We next asked whether Tor signaling is essential for zfh2-mediated EB-growth. To this end, we inhibited the activity of Tor genetically, by over-expressing the Tor inhibitor complex TSC1 and TSC2, and pharmacologically, by feeding flies the Tor inhibitor rapamycin. Both manipulations are sufficient to block zfh2-mediated EB growth ([Fig 5B](#pgen.1008553.g005){ref-type="fig"}), strongly suggesting that Tor signaling acts downstream genetically or temporally of zfh2-induced activation. To further test this hypothesis, we activated Tor signaling through the EB-specific over-expression of Rheb. Similar to what we observed for zfh2, this results in a robust EB growth but no significant increase in nuclear size (Figs [5C](#pgen.1008553.g005){ref-type="fig"} and [S4C](#pgen.1008553.s004){ref-type="supplementary-material"}), suggesting that in EBs cell growth can be genetically separated from endoreplication. Remarkably, we found that co-expression of zfh2RNAi constructs is sufficient to block Rheb-induced growth ([Fig 5C](#pgen.1008553.g005){ref-type="fig"}). Furthermore, we observed that Rheb expression and its associated EB growth fail to induce morphological changes, protrusion formation and ISC proliferation ([Fig 5D, 5E and 5F](#pgen.1008553.g005){ref-type="fig"}), strongly suggesting that Tor signaling control cell growth but does not control EB activation.

The Ras/MAPK pathway has been recently shown to also control EB growth, more specifically under tissue damage conditions \[[@pgen.1008553.ref012]\]. Similar to what we observed with Rheb over-expression, we found that although activation ERK signaling by expressing the active form Rolled^SEM^ cause a detectable EB growth ([S5A Fig](#pgen.1008553.s005){ref-type="supplementary-material"}). However, it does not significantly induce changes in EB morphology, protrusions or affect ISC proliferation rates ([S5B](#pgen.1008553.s005){ref-type="supplementary-material"}, [S5C and S5D Fig](#pgen.1008553.s005){ref-type="supplementary-material"}). In addition, although expressing a dominant form of Ras (Ras^N17^) in EBs is sufficient to significantly reduce zfh2-mediated EB growth, it does not affect cell activation, measured by cell circularity and protrusions ([S5E](#pgen.1008553.s005){ref-type="supplementary-material"}, [S5F and S5G Fig](#pgen.1008553.s005){ref-type="supplementary-material"}).

Altogether, these data greatly improve our understanding of the sequence of event leading to EB differentiation. We show that EB activation can be separated from growth pathways and that zfh2-mediated activation is essential to prime EBs for the Tor and Ras/MAPK pathways to promote cell growth.

zfh2 and insulin signaling act in parallel to control a subset of phenotypes associated with EB activation {#sec008}
----------------------------------------------------------------------------------------------------------

The insulin signaling pathway controls ISC proliferation and EB growth \[[@pgen.1008553.ref009], [@pgen.1008553.ref010], [@pgen.1008553.ref034], [@pgen.1008553.ref035]\]. Particularly relevant to our study, insulin signaling is known to control very early EB growth and the degradation of E-cadherin adhesion between EBs and their neighboring stem cells, regulating ISC in a non-cell autonomous manner \[[@pgen.1008553.ref011]\]. This suggested to us that, like zfh2, this pathway may act during the dormant to activated EB transition and could regulate the process of EB activation itself. Therefore, we investigated the genetic interaction between InR signaling and zfh2 in EBs. As reported previously, activation of the insulin signaling pathway in EB, by over-expression of an activate form of the insulin receptor (InRact) is sufficient to induce EB growth and drive ISC proliferation ([Fig 6A and 6B](#pgen.1008553.g006){ref-type="fig"}). However, we found no evidence that this manipulation induces EB morphological changes or the formation of cell protrusions ([Fig 6C and 6D](#pgen.1008553.g006){ref-type="fig"}), suggesting that at least some aspects of EB activation that are controlled by zfh2 are InR-independent. To confirm this notion, we tested the requirement for the insulin pathway in zfh2-induced activation. We found that, blocking insulin signaling by expression of a strong dominant negative form of InR does not affect zfh2 ability to induce EB growth and non-cell autonomous ISC proliferation ([Fig 6E and 6F](#pgen.1008553.g006){ref-type="fig"}). This further suggest that zfh2 over-expression is sufficient to bypass the requirement of InR for EB growth that has previously described \[[@pgen.1008553.ref011]\]. Finally, we performed the converse epistasis assay by activating insulin signaling in a background where zfh2 expression was decreased by dsRNA. In these conditions, we found that zfh2 is dispensable for InR-induced ISC proliferation ([Fig 6C](#pgen.1008553.g006){ref-type="fig"}) and we detected a small but not significant decrease in EB cell size ([Fig 6A](#pgen.1008553.g006){ref-type="fig"}), suggesting that zfh2 does not function genetically downstream of the InR signaling cascade to regulate EB growth and the subsequent non-cell autonomous ISC proliferation.

![zfh2 and insulin signaling act in parallel to control enteroblast activation.\
(A, B, C, D) insulin receptor activity is induced in EBs by driving expression of the activated form of the insulin receptor (InRAct) using GBEGal4 ts. EBs are labeled by GBEGal4ts\> mCD8GFP. (A) zfh2 is knocked-down in EBs by driving dsRNA against zfh2 using GBEGal4ts. Cell size of EBs is quantified by measuring cell area of individual cells. zfh2 is not required for InR-mediated EB growth. (B) zfh2 is knocked-down in EBs by driving dsRNA against zfh2 using GBEGal4ts. Mitoses per gut are detected via immunohistochemistry against phosphoHistone H3. Insulin receptor activity in EBs induces ISC proliferation non-cell autonomously, bypassing the requirement for zfh2-mediated activation. (C, D) Inducing insulin receptor activity in EBs is not sufficient to induce changes in cell morphology, measured by cell circularity (C), or formation of membrane protrusions (D). (E, F) Insulin receptor activity is blocked in EBs by driving expression of the dominant negative form of the insulin receptor (InRDN) using GBEGal4ts. zfh2 is over-expressed by driving the zfh2EAB transgene using GBEGal4ts. Cell size of EB are quantified by measuring cell area of individual cells (E). Mitoses per gut are detected via immunohistochemistry against phosphoHistone H3 (F). Blocking insulin receptor activity in EBs blocks cell growth and ISC proliferation. Over-expression zfh2 rescues these phenotypes. In A,B,C,E,F values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test. In D p-values are calculated using the Mann-Whitney test.](pgen.1008553.g006){#pgen.1008553.g006}

Together, these genetic interactions demonstrate that InR signaling can promote growth in zfh2-deficient EBs and that, conversely, zfh2 can induce growth in the absence of InR activity. However, InR is not sufficient to induce protrusion or morphological changes. Therefore, our work strongly suggests that InR and zfh2 act in parallel to control some aspects of early EB growth, but that zfh2 has a unique role in the migratory phenotype associated with EB activation.

Maintaining zfh2 expression prevents enterocyte terminal differentiation {#sec009}
------------------------------------------------------------------------

During our zfh2 gain-of-function experiments, we noticed that prolonged over-expression of zfh2 using the esgGal4ts drivers leads to dramatic disruption of the intestinal architecture. While the wild-type young intestinal epithelium is invariably organized in a monolayer, we observed the formation of multilayered cell clusters at day 3 of zfh2 induction. This ultimately leads to intestines where the epithelium is so overgrown that the lumen becomes undetectable by day 10 ([Fig 7A](#pgen.1008553.g007){ref-type="fig"}). This phenotype is remarkable in the anterior and the posterior midgut ([S6C Fig](#pgen.1008553.s006){ref-type="supplementary-material"}), but limited in the copper cells region (mid midgut) where proliferation is often reduced and zfh2-expressing tumors are much smaller. Importantly, we found that in both posterior and anterior midgut, cell division is limited to basal layers of the tumor ([S6C Fig](#pgen.1008553.s006){ref-type="supplementary-material"}), suggesting that the tumor phenotype is driven by proliferation of ISCs.

![Maintaining zfh2 expression prevents enterocyte terminal differentiation.\
(A,B,C,D,E) Representative confocal image of the posterior midgut. zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using esgGal4ts. (A) Transverse view of the posterior midgut. Visceral muscle is stained via phalloidin conjugated with Cy5. Long term zfh2 over-expression leads to multilayered escargot expressing tumors. (B) ISCs and EEs are labeled via immunohistochemistry against delta (membrane signal) and prospero (nuclear signal) respectively. Limited number of cells within the zfh2 over-expression tumors are ISCs or EEs. (C) ISCs and EBs are labeled via immunohistochemistry against Sox21a. zfh2 over-expression tumor cells show high levels of sox21a protein. (D) ECs are labeled via immunohistochemistry against Pdm1. zfh2 over-expression tumor cells are Pdm1-negative. (E) βGalactosidase, from the EB-specific reporter Su(H)GBELacZ, is detected via immunohistochemistry. Most of the cells located in basal layers of the zfh2 over-expressing tumors are positive for this reporter. However, transverse view shows that only the basal layers of these tumors are LacZ positive. (F) Representative confocal image of the posterior midgut. zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using GBEGal4ts. EBs are labeled via GBEGal4ts\>GFP. Long term EB-specific zfh2 over-expression leads to accumulation of EBs.](pgen.1008553.g007){#pgen.1008553.g007}

Multilayered tumors comprised of adult intestinal progenitors have been reported when terminal differentiation of EBs into the ECs is blocked \[[@pgen.1008553.ref014], [@pgen.1008553.ref015]\]. To test whether the cells that accumulate in these tumor-like epithelia are indeed EBs and what stage of their differentiation may be arrested, we used a combination of ISC, EE, EB and EC markers. We found that in these overgrown epithelia only a few cells in the basal layer express the ISC marker Delta or the EE marker Prospero ([Fig 7B](#pgen.1008553.g007){ref-type="fig"}). Importantly, we found that in both posterior and anterior midgut, cell division is limited to basal layers of the tumor ([S6C Fig](#pgen.1008553.s006){ref-type="supplementary-material"}), suggesting that the tumor phenotype is driven by proliferation of these ISCs. To confirm that most tumor cells are EBs, we investigated later differentiation markers. We found that, in addition to escargot, they expressed high levels of Sox21a and are negative for the EC marker Pdm1 ([Fig 7C and 7D](#pgen.1008553.g007){ref-type="fig"}). Finally, clonal analysis confirmed that maintaining zfh2 expression in intestinal lineages block terminal differentiation, as shown by the large reduction in the number of Pdm1-positive cells in zfh2-overexpressing MARCM clones compared to control clones ([S6 Fig](#pgen.1008553.s006){ref-type="supplementary-material"}).

Expression of Notch activity reporters, such as the Su(H)GBE-LacZ and Su(H)GBEGal4 lines, has been used as an historical marker of EBs \[[@pgen.1008553.ref030]\]. Interestingly, in the multilayered intestines of esgGal4ts\>zfh2 animals, we observed several layers of GBE-positive cells basally. However, the many apical layers of these tumor-like epithelia are composed exclusively of GBE-negative esg-positive cells ([Fig 7E](#pgen.1008553.g007){ref-type="fig"}). In addition, multilayered cell clusters form when zfh2 is specifically over-expressed in EBs using the GBEGal4ts driver, although at a slightly slower pace and not to the same magnitude that when using the esgGal4ts driver ([Fig 7F](#pgen.1008553.g007){ref-type="fig"}). This confirms that this phenotype is cell autonomous and suggests that, like the GBE-LacZ reporter, the activity of GBEGal4 driver is lost in late differentiated EBs, resulting in a transient zfh2 over-expression and weaker phenotype in GBEGal4ts\>UAS-zfh2^EAB^ animals. Together, these data demonstrate that ectopically maintained zfh2 expression blocks terminal differentiation into ECs and arrest EBs in a previously uncharacterized esg-positive Sox21a-high Notch-negative cell state.

Discussion {#sec010}
==========

zfh2 and enteroblast activation {#sec011}
-------------------------------

In this study, we characterized the stepwise series of events leading to intestinal progenitor differentiation and the role of the transcription factor zfh2 in early progenitor activation.

Previous work has shown that challenging homeostatic conditions, either via bacterial infection or chemical stressors, is sufficient to induce phenotypical changes in EBs leading to terminal differentiation into the EC fate \[[@pgen.1008553.ref013]\]. The changes associated with early EB activation have been described as Epithelial-Mesenchymal Transition (EMT)-like, as they are coupled with re-organization of the cytoskeleton and migratory behavior. Our work establishes a sequential order and gives temporal resolution for some of these events ([Fig 8](#pgen.1008553.g008){ref-type="fig"}). We show that the morphological changes, associated with EB migration, and the formation of thin membrane protrusions, phenotypes that we describe as being part of the activation process, take place within 6 hours of tissue damage. Interestingly, while morphological changes persist, suggesting that EBs remain migratory, thin protrusions are lost 12 hours after induction suggesting a shift in signaling ([Fig 8A](#pgen.1008553.g008){ref-type="fig"}). It will be interesting to ask whether cell surface receptors or signaling ligands transiently accumulate in these structures, as they do in other stem cell compartment and developing tissues \[[@pgen.1008553.ref036]\], and test the possibility that EBs use these cellular processes to determine migration orientation relative to sites of tissue damage. In addition to EBs, it may also be interesting to test whether similar processes are involved in early cell differentiation in the Prospero-positive endocrine lineage.

![Model presenting the function of zfh2 and the processes of enteroblast activation and differentiation.\
(A) zfh2 controls the activation of EBs, as shown by the formation of thin membrane protrusion and morphological changes, 6 hours after stress exposure. Protrusions are lost 12 hours after activation. (B) EB activation and loss of cell adhesion induces compensatory stem cell proliferation. (C) Maintaining ectopic zfh2 activity in late EBs results in a block of differentiation, growth and tumor formation. (D) Notch signaling is inactive in zfh2 overexpression-induced tumors, suggesting that Notch activity is lost before esg down-regulation and other late differentiation processes.](pgen.1008553.g008){#pgen.1008553.g008}

In parallel to our improved description of the early activation process, previous work has shown that EB early differentiation indirectly affects ISC proliferation ([Fig 8B](#pgen.1008553.g008){ref-type="fig"}). Small dormant EBs inhibit proliferation of their neighboring ISC in a contact dependent manner via high levels of DE-Cadherin; degradation of DE-cadherin is controlled by the insulin signaling pathway in EBs to promote ISC proliferation \[[@pgen.1008553.ref011]\]. In addition, blocking terminal differentiation induces non-cell autonomous ISC proliferation and tumorigenesis, through the activation of several pathway including JAK/STAT and EGF \[[@pgen.1008553.ref014], [@pgen.1008553.ref015], [@pgen.1008553.ref032]\]. Here we found that zfh2-mediated EB activation is sufficient to promote ISC proliferation non-cell autonomously and our data suggest that this induction doesn't require the activity of the insulin receptor. We also show that InR signaling is not sufficient to promote EB activation, defined by morphological changes and the formation of membrane protrusions. Together, these observations support a model where both InR and zfh2 can induce independently EB growth and ISC proliferation but where zfh2 is uniquely required for the migratory EB phenotype. Unfortunately, at this point, it is unclear how InR activity controls to E-cadherin degradation. It would be interesting in future studies to test whether zfh2 regulates ISC proliferation non-cell autonomously through similar mechanisms, once these have been identified. The function of zfh2 would guarantee that EB migration and early growth are coordinated with its detachment from the neighboring stem cell and compensatory ISC proliferation to maintain tissue homeostasis.

Downstream of the initial process of activation, EB growth also requires zfh2-mediated activation. In addition, like InR signaling, while activation of TOR or MAPK pathways is sufficient to promote EB growth, it does not result in EB activation or ISC proliferative response. This strongly suggests that EB growth and growth-related signaling pathways are temporally and genetically downstream of zfh2-mediated activation.

zfh2, enteroblast differentiation and tumorigenesis {#sec012}
---------------------------------------------------

On the other end of the differentiation process, several factors have been shown to regulate terminal differentiation of EBs into ECs. Here we show that maintaining zfh2 expression in late EBs prevents their differentiation and causes the formation of highly proliferative multilayered tumors, suggesting that zfh2 expression and activity need to be turned "off" for terminal differentiation ([Fig 8C](#pgen.1008553.g008){ref-type="fig"}). Interestingly, non-proliferative tumorigenic EBs have also been reported when the transcription factor Sox21a is inhibited \[[@pgen.1008553.ref014], [@pgen.1008553.ref015], [@pgen.1008553.ref032]\]. However, we show that over-expression of zfh2 is sufficient to increase and maintain high levels of Sox21a, suggesting that these two types of EB tumors differ. In addition, we show that Notch activity is lost in the most apical layers of cells that accumulate when zfh2 expression is sustained, whereas Notch activity is maintained in Sox21a mutant tumors. Finally, zfh2-mediated tumors are more aggressive than most Sox21a mutant tumors, as they are become obvious by day 3 of transgene activation and lead to massive multilayering in both the anterior and posterior midgut by day 10. Interestingly, high levels of Sox21a are sufficient to drive EB differentiation into Pdm1-positve ECs \[[@pgen.1008553.ref014], [@pgen.1008553.ref015]\]. Therefore, our data support a model where zfh2-overexpressing EBs are arrested later in differentiation than Sox21-mutant EBs. This also suggests that in these late EBs, maintaining zfh2 expression directly or indirectly inhibits the ability of Sox21a to drive differentiation thus leading to a chronic expression of self-renewal factors. We anticipate that identifying the target genes of zfh2 will shed light on the molecular mechanisms of this interaction.

Our results also strongly suggest that Notch activity downregulation precedes escargot and Sox21a downregulation, likely when the EB migrates away from its neighboring stem cell thus losing the Delta signal required for EB commitment and early differentiation \[[@pgen.1008553.ref030], [@pgen.1008553.ref037]\] ([Fig 8D](#pgen.1008553.g008){ref-type="fig"}). This further improves our understanding of the several cellular transitions taking place during the EB differentiation process and suggests that other intermediate phenotypes have yet to be identified in this lineage. Other genetic elements have been shown to regulate late EB differentiation events. The microRNA mir-8, that has been hypothesized to promote proper precursor epithelial reintegration and terminal differentiation by inhibiting expression of escargot \[[@pgen.1008553.ref013], [@pgen.1008553.ref038]\]. Our results show that long-term zfh2 over-expression induces maintenance of a mesenchymal-like state in late EBs, suggesting that mir-8 dependent terminal differentiation and re-integration are temporally downstream of zfh2 activity loss. Despite the recent advances of live imaging in the intestinal lineage \[[@pgen.1008553.ref039]\], we do not have sufficient temporal resolution to visualize the sequence of events leading to EB terminal differentiation. Further experiments will be required to understand the exact relationships between these critical differentiation regulators.

Of note, another gene that has been recently implicated in maintenance of stemness in this tissue is the *Drosophila* ZEB protein homolog zfh1 \[[@pgen.1008553.ref013]\]. Despite being similarly named, there is very low similarity (10.2%) between these two proteins: zfh1 has 1 homeodomain and 7 zinc-fingers, while zfh2 has 3 homeodomains and 17 zinc fingers. This differences in domain number and organization makes it very unlikely that these 2 proteins have overlapping target genes. However, it would be interesting to test possible genetic interactions between zfh2 and zfh1 in further studies.

Finally, our study uncovers the role of zfh2 in the EMT-like EB activation and MET-like EB terminal differentiation. In mammals, the zfh2 homolog ATBF1/ZFHX3 (AT-motif binding factor/zinc finger homeobox 3) is a demonstrated tumor suppressor, found frequently mutated in a large spectrum of human cancers (e.g. prostate cancer \[[@pgen.1008553.ref022], [@pgen.1008553.ref025]\]). However, the precise mechanism(s) by which ATBF1 controls tumorigenesis and metastasis remain largely elusive. More interestingly, in vitro studies correlate over-expression of another zfh2 homolog, ZFHX4, with cancer cell migration and invasiveness\[[@pgen.1008553.ref027]\]. It is tempting to propose that further investigating the function of zfh2 in the *Drosophila* intestinal lineage will generate new hypotheses regarding the role of ATBF1 and ZFHX4 in tumor formation and progression.

Mechanism and regulation of zfh2 activity {#sec013}
-----------------------------------------

Our study demonstrates that zfh2 controls EB activation, growth and terminal differentiation. However, its direct target genes and how it controls, directly or indirectly, critical EB processes and signaling pathways remain unclear. While zfh2 regulates targets of Notch signaling during tarsal development \[[@pgen.1008553.ref019]\], it is unlikely that it functions in a similar mechanism in EBs as knocking-down its expression does not affect Notch reporters activity. Our work has shown that zfh2 mediated activation is sufficient to induce Tor activity, and that this increase of Tor activity leads to EB growth. In EBs, Tor signaling controls cell growth via the TORC1 complex \[[@pgen.1008553.ref009]\] and is regulated by Notch signaling through the regulation of TSC2 expression \[[@pgen.1008553.ref010]\]. However, we don't know how the transcription factor zfh2 may regulate the TORC1 signaling cascade, but it is likely a secondary effect of EB activation rather than a direct regulation. We have further shown that zfh2 over-expression is sufficient to drive a host of phenotypes, including formation of membrane protrusions and changes in cell shape, suggesting that zfh2 mediated activation leads to a remodeling of the cytoskeleton. Again, the mechanisms by which zfh2 controls EB morphology and potentially migration remain unknown.

Finally, here we show that zfh2 is expressed in both ISCs and EBs but we focused on the role that zfh2 has in EB activation and differentiation. Thus far, we have found no phenotype associated with zfh2 loss in ISCs. The mechanism by which zfh2 activity is regulated in an EB specific manner remains to be elucidated. Activity of ATBF1, one of the zfh2 mammalian homolog, has been shown to be controlled by its subcellular localization \[[@pgen.1008553.ref040], [@pgen.1008553.ref041]\], however we didn't observe any difference in either expression level or cellular localization of zfh2 between ISCs and EBs. Alternatively, zfh2 may be regulated by post-translational modifications; for example, ATBF1 has been shown to be SUMOylated and also phosphorylated \[[@pgen.1008553.ref041], [@pgen.1008553.ref042]\]. Another possible mechanism for gene target specificity in EB could be combinatorial regulation, either via direct or indirect interaction with other transcription factors. Biochemical analysis of zfh2 and its potential partners in the adult intestine will be required to make significant progress in our understanding of the regulation of zfh2 activity.

Materials and methods {#sec014}
=====================

Drosophila stocks and rearing {#sec015}
-----------------------------

All flies were raised on standard yeast and molasses-based food, at 25°C and 65% humidity, on a 12 h light/dark cycle. For TARGET experiments flies were raised at 18°C and shifted to 29°C 4--7 days after eclosion.

The following strains were obtained from Bloomington *Drosophila* stock center: w1118, UAS-zfh2RNAi50643 (50643), UAS-zfh2EAB (56545), zfh2Gal4GMR73G11 (81071), esgLacZ (10359), UAS-Gtrace (28280), UAS-Rheb (9688), UAS-InRwt (8262), UAS-InRDN (8252), UAS-InRAct (8263), UAS-mCD8RFP (27391), UAS-MoesinGFP (31775), UAS-RasN17 (4845), UAS-ThorRNAi (80427). From Vienna *Drosophila* RNAi Center: UAS-zfh2RNAi13305 (v13305). The following strains were gifts from: Su(H)GBELacZ by S.Bray, esgGal4ts,Su(H)GBEGal80 by H. Jasper, DeltaGal4 and Su(H)GBEGal4 by S.X.Hou, UAS-TSC1+TSC2 by M. Tatar, ssg-Gal4 by S. Hayashi, UAS-Rolled SEM by M. Mlodzik, UAS-zfh2RNAiSp and zfh2Gal4LP30 by FJ Díaz-Benjumea.

For each of the described experiments, the genotype of the flies used is detailed in [S1 File](#pgen.1008553.s007){ref-type="supplementary-material"}.

Immunohistochemistry and imaging {#sec016}
--------------------------------

Female fly intestines were dissected in PBS 1X solution and then fixed in Fixation Buffer containing 100 mM glutamic acid, 25 mM KCl, 20 mM MgSO4, 4 mM sodium phosphate, 1 mM MgCl2, and 4% formaldehyde for 45 minutes at room temperature. Samples were blocked using Blocking buffer containing PBS 1X, 0.5% BSA, and 0.1% Triton X-100. Samples were then incubated in the same buffer containing primary antibodies over-night at 4°C \[anti-phospho-Histone H3 from Millipore (1:2000), anti-Beta-Galactosidase from DHSB (1:500), anti-Prospero from DHSB (1:200)\]. Fluorescent secondary antibodies were obtained from Jackson Immunoresearch. DNA was stained using Hoechst and Visceral muscle was stained using Alexa Fluor 647 Phalloidin (from Invitrogen, 1:400). For Delta (from DHSB, 1:500), Sox21a (generated in the lab \[[@pgen.1008553.ref043]\], 1:5000), p4EBP (from Cell signaling technologies, 1:200), zfh2 (kindly provided by Chris Doe, 1:200) and PDM1 (kindly provided by Xiaohang Yang and Cai Yu, 1:1000) staining samples were fixed in Fixation Buffer and Heptane, dehydrated with 100% Methanol and progressively re-hydrated in blocking Buffer. Confocal imaging was done using the Leica SP5 system and processed with Adobe Photoshop CS6.

Imaging and analysis of non-fixed samples {#sec017}
-----------------------------------------

Samples were dissected in 1XPBS solution, immediately mounted in Voltalef 10S oil (VWR). Confocal imaging was done using the Leica SP5 system and completed within 30 min of dissection. For analysis of cell circularity images were treated using FIJI. A composite image was created for each ROI, a Gaussian Blur Filter was used to remove noise and remove membrane protrusions. Images were then converted to Binary before measuring circularity using FIJI. For analysis of membrane protrusions untreated z-stacks were manually analyzed.

In all quantification of cell area, cell morphology and membrane protrusions, at least 10 ROI were analyzed for each condition from at least 4 different female flies. Numerical values are presented in [S2](#pgen.1008553.s008){ref-type="supplementary-material"} and [S3](#pgen.1008553.s009){ref-type="supplementary-material"} Files.

Quantification of protein levels by immunofluorescence intensity {#sec018}
----------------------------------------------------------------

To quantify fluorescence intensity, images were analyzed using FIJI \[[@pgen.1008553.ref044]\]. For each EB or ISC GFP-positive cell, a single focal plane through the center of the cell was selected. First, the GFP signal was used to delineate individual cell area. The mean fluorescence intensity of pixels for the antibody staining channel was measured within the cell area. This value was then normalized to mean background pixel intensity in a comparable neighboring region of interest selected between GFP cells. The data are presented as normalized pixel intensity within GFP-positive cells. Numerical values are presented in [S2](#pgen.1008553.s008){ref-type="supplementary-material"} and [S3 Files](#pgen.1008553.s009){ref-type="supplementary-material"}.

Western blot analysis of proteins {#sec019}
---------------------------------

Female fly intestines were dissected in PBS 1X. Proteins were extracted in Laemmli sample buffer, separated on a 15% SDS poly-acrylamide gel and transferred according to standard procedures. Antibodies directed against B-actin (Cell signaling technologies, 1:5000) and p4EBP (Cell signaling technologies, 1:1000) were used.

Rapamycin treatment {#sec020}
-------------------

Rapamycin (Fisher Scientific) was dissolved in DMSO and added to the food at a final concentration of 200μM. 4--7 days old flies were shifted to food containing either DMSO or DMSO and Rapamycin for 4 days before being shifted to 29°C for 3 days. Food with either DMSO or DMSO and Rapamycin was changed every 2 days.

DSS, Paraquat and Ecc15 treatments {#sec021}
----------------------------------

For DSS stress exposure, 4--7 days old flies were starved for 6 hours in empty vials before being transferred to vials containing a filter paper with either 5% Sucrose (AMRESCO) or 5% Sucrose and 4% DSS (Sigma Aldrich). For Paraquat stress exposure flies were similarly starved before being transferred to vial containing either 5% Sucrose or 5 mM Paraquat dissolved in 5% Sucrose. Erwinia carotovora carotovora15 (Ecc15) was grown overnight in LB medium at 30°C and harvested by centrifugation. The bacterial pellet was then resuspended in a 5% Sucrose solution before being fed to 6 hours starved flies via filter paper. For acute stress flies were dissected at the indicated times.

Mosaic analysis with a repressible cell marker clones (MARCM) and lineage tracing {#sec022}
---------------------------------------------------------------------------------

Clones were generated using the following MARCM stock: MARCM19 (hsFLP, tubGal80, FRT19A; T80Gal4, UAS-GFP). 4--7 days old flies were heat-shocked at 37°C for 30 min for clone induction, and then transferred at 25°C for 7 days before dissection and immunohistochemistry.

Lineage tracing used the GTRACE system (w\*;UAS-RedStinger,UAS-FLP,UbiFRTStopFRTStinger) combined with the temperature sensitive driver GBEGal4ts. 4--7 days old flies were shifted at 29°C for 3 days to allow for transgene expression. Flies were then starved for 6 hours in empty vials before being transferred for 24 hours to vials containing either 5% Sucrose or 5% Sucrose and 4% DSS. Flies were shifted back to regular food for 2 days before dissection and immunohistochemistry.

Supporting information {#sec023}
======================

###### zfh2 is expressed in ISCs and EBs.

\(A\) Representative confocal image of the posterior midgut. EB are labeled by GBEGal4ts\>mCD8GFP. Sox21a and zfh2 are detected via immunohistochemistry in ISC and EB. Flies are fed either DSS or Sucrose for 6, 18 or 40 hours before dissection and fixation. zfh2 protein is detected via immunohistochemistry. (B) zfh2 protein levels in EB are measured by quantification of zfh2 fluorescence in individual cells. Values are normalized to neighboring ISC. zfh2 protein is expressed at similar levels in both ISC and EB. (C) zfh2 protein levels in EB and ISC are measured by quantification of zfh2 fluorescence in individual cells. zfh2 protein levels increase after DSS mediated stress. In B and C, values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test.

(TIF)

###### 

Click here for additional data file.

###### zfh2 does not controls intestinal cell composition but regulates EB cell size.

\(A\) ISC and EB are labeled by esgGal4ts\>GFP. ISC and enteroendocrine cells are labeled via immunohistochemistry against delta and prospero respectively. zfh2 is knocked-down by driving dsRNA against zfh2 using esgGal4ts. Number of ISC (GFP+,Delta+), EB (GFP+,Delta-) and ee (Prospero+) cells are quantified and normalized to the total number of cells per ROI. Each value represents a ROI. (B) ISC and EB are labeled by esgGal4ts \> GFP. ISC and enteroendocrine cells are labeled via immunohistochemistry against delta and prospero respectively. zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using esgGal4ts. zfh2 is knocked-down by driving dsRNA against zfh2 using esgGal4ts. Nuclear size of ISCs and EBs are quantified by measuring nuclear area of individual cells. zfh2 knock down via dsRNA blocks endoreplication in EBs. (C) EB are labeled by GBEGal4ts\>mCD8GFP. zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using GBEGal4ts. zfh2 is knocked-down by driving dsRNA against zfh2 using GBEGal4ts. Nuclear size of EBs are quantified by measuring nuclear area of individual cells. zfh2 knock down via dsRNA blocks endoreplication in EBs. In A, B and C, values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test.

(TIF)

###### 

Click here for additional data file.

###### Stress- and zfh2-mediated induction of EB activation.

\(A\) Representative confocal images of non-fixed posterior midguts. EB are labeled by GBEGal4\>mcD8GFP. Stress mediated EB activation is induced by feeding flies Paraquat or Ecc15 for 3--4 hours. Paraquat and ECC15 mediated stress is sufficient to increase the number of EBs with membrane protrusions (B) and decrease circularity (C). (D) Representative confocal images of non-fixed posterior midguts. EBs are labeled by GBEGal4\>mcD8RFP, actin is labeled by GBEGal4\>Moesin-GFP. Stress mediated EB activation is induced by DSS for 6 hours. Membrane protrusions contain actin. (E) Representative confocal images of posterior midguts. EB are labeled by GBEGal4ts\>GFP. zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using GBEGal4ts. Sox21a is detected via immunohistochemistry. (F) Quantification of sox21a protein levels in EB by quantifying mean sox21a fluorescence levels in individual cells. zfh2 over-expression in EB increases sox21a levels. In C and F values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test. In B p-values are calculated using the Mann-Whitney test.

(TIF)

###### 

Click here for additional data file.

###### zh2 over-expression induces TOR activity.

\(A\) zfh2 is over-expressed by driving the UAS-zfh2EAB transgene using esgGal4 ts. 4EBP (Thor) is knocked-down in EB by driving dsRNA using EsgGal4ts. Tor activity is stimulated by over-expression of the Tor activator Rheb. p4EBP is labeled via immunohistochemistry. (B) Protein levels are quantified by measuring mean fluorescence intensity of individual cells. Inducing EB activation via zfh2 over-expression is sufficient to increase Tor signaling activity. (C) EB are labeled by GBEGal4ts \> mcD8GFP. zfh2 is over-expressed by driving UAS-zfh2EAB using GBEGal4ts. Tor activity is induced by over-expressing Rheb using GBEGal4ts. Nuclear size of EB are quantified by measuring nuclear area of individual cells. In B and C values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test.

(TIF)

###### 

Click here for additional data file.

###### Interaction between zfh2 and the Ras/MAPK pathway.

(A,B,C,D) ERK activity is induced in EB by driving the expression of the activated form of ERK (RolledSEM) using GBEGal4ts. EB are labeled by GBEGal4ts\> mCD8GFP. (A) Cell size of EB are quantified by measuring cell area of individual cells. ERK activity induces EB growth. Inducing ERK activity is not sufficient to induce changes in cell morphology, measured by cell circularity (B), an increase on mitoses per gut, detected via immunohistochemistry against phosphoHistone H3 (C), or formation of membrane protrusions (D). (E,F,G) Ras activity is blocked in EB by driving expression of the dominant negative form of Ras (RasN17) using GBEGal4ts. zfh2 is over-expressed by driving the zfh2EAB transgene using GBEGal4ts. (E) Cell size of EB are quantified by measuring cell area of individual cells. Blocking Ras activity blocks EB growth cell-autonomously. Inducing EB activation induces growth in RasN17 EB. Blocking Ras activity is not sufficient to block changes in cell morphology, measured by cell circularity (F) or formation of membrane protrusions (G) associated with zfh2 mediated EB activation. In A, B, C, E, F values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test. In D, G p-values are calculated using the Mann-Whitney test.

(TIF)

###### 

Click here for additional data file.

###### Long-term over-expression of zfh2 blocks EB differentiation and promotes tumor formation.

\(A\) Representative confocal images of control and zfh2 over-expressing MARCM clones in the posterior midgut, 7 days after induction. ECs are labeled via immunohistochemistry against Pdm1. (B) Proportion of EC per clone is quantified showing that UAS-zfh2 EAB clones contain a significantly reduced the number of EC compared to controls. (C) Representative confocal images of the posterior and anterior midgut. zfh2 is over-expressed by driving UAS-zfh2EAB using esgGal4ts. Mitotic cells are identified via immunohistochemistry against phosphoHistone H3 (arrowhead). Long term zfh2 over-expression leads to multilayered escargot expressing tumors in both the posterior and the anterior midgut. A high number of mitotically active cells are present in the basal layer of the tumor. Gut lumen is indicated by yellow brackets in the transverse views. In B values are presented as average +/- s.e.m, and p-values are calculated using a two-tailed Student's t-test.

(TIF)

###### 

Click here for additional data file.

###### Detailed genotypes.

For each figure (main figures and supplementary figures), the genotypes of all the animals used in the described experiments is detailed here.

(DOCX)

###### 

Click here for additional data file.

###### Numerical Values--Main figures.

The numerical values presented in each of the main figure (Figs [1](#pgen.1008553.g001){ref-type="fig"}--[7](#pgen.1008553.g007){ref-type="fig"}) are reported here.

(XLSX)

###### 

Click here for additional data file.

###### Numerical Values--Supplementary figures.

The numerical values presented in each of the supplementary figures ([S1](#pgen.1008553.s001){ref-type="supplementary-material"}--[S6](#pgen.1008553.s006){ref-type="supplementary-material"} Figs) are reported here.

(XLSX)

###### 

Click here for additional data file.
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Dear Dr Biteau,

Thank you very much for submitting your Research Article entitled \'Zfh2 controls cell activation and differentiation in the adult Drosophila intestinal lineage\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Aurelio A Teleman

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors report here that Zfh2 is an ISC/EB specific factor that regulates EB activation and differentiation to ECs. Furthermore, they report that Zfh2 is required and sufficient to drive activation of EBs. This includes cell shape change, cell size increase, transient formation of thin membrane protrusions and increased compensatory ISC proliferation. Additionally, they report that Zfh2 is upstream of TOR and MAPK and parallel to insulin signaling and that Zfh2 overexpression results in dysplastic lesions.

Overall this study explores an important question about the early stages of differentiation of intestinal progenitors- a process that is not well-understood. The data provided about Zfh2's role in EB activation (i.e., cell shape and size change, protrusion formation, requirement for differentiation) are convincing; however, the mechanism(s) into how Zfh2 is regulated or regulates EB activation/differentiation needs to be strengthened. The claim that Zfh2 is upstream of TOR and MAPK and parallel to insulin signaling is not well supported with the data provided.

I have outlined my concerns below:

1\. The role of Zfh2 needs to be put into context with other pathways known to regulate EB growth and differentiation, e.g. Notch or JAK-STAT signaling. The authors describe in the introduction that Notch controls Zfh2 expression in developing fly wing discs (page 6). Does the Notch signal in EBs promote Zfh2 expression or activity in EBs? This is important since the authors report that Zfh2 is required in EBs that have received a Notch signal (GBE+) for their growth and differentiation to ECs.

2\. The study nicely tries to establish a standard to study EB activation and uses DSS stress to induce EB activation. It is important though to demonstrate that these activation events (i.e., protrusion formation) occur upon a variety of stresses shown to promote ISC proliferation (and thus likely increase activated EB numbers), e.g. pathogen infection, oxidative stress, DNA damage. Are these morphological changes common features of activation in other stress conditions or rather only a response to DSS treatment which affects the extracellular matrix. Antonello et al., 2015 reported EB protrusion formation only under non-stress conditions. Do EBs differentiating into EEs also form protrusions? Presumably, they also should.

3\. The authors show that Zfh2 is required for cell size increase but is not sufficient to promote endoreplication. This data is confounding since the authors claim that Zfh2 also promotes TOR signaling which has been shown to promote endoreplication in fly tissues (Zielke et al., 2011).

4\. In Figure 3D, why are there large protrusions observed in the control (without DSS)?

5\. In Figure 4A, the overlap of Pdm1 with GBE\>trace is difficult to observe. A separation of fields will help here. Is Zfh2 required for EE differentiation?

6\. Do Zfh2 levels affect E-Cadherin levels in EBs? The text on page 23 states that Zfh2 can induce DE-Cadherin degradation, but this data is not in the manuscript.

7\. The data shown to support TOR activation by Zfh2 is not yet convincing for the following reasons: 1) the phospho-4EBP antibody in Fig. 5A needs to be validated, preferably in situ (e.g., knockdown of 4EBP, overexpression of Rheb); 2) in Fig. 5B, Zfh2 overexpression increases phospho-4EBP in all esg+ cells (which presumably includes ISCs) in the field, yet there is no effect on ISC size or proliferation (Fig. 4C). This is surprising since it has been reported that activated ISCs can increase in size (Jiang et al., 2009); 3) in Fig. 5B, the activation of TOR signaling by Zfh2 overexpression is not terribly convincing, particularly since the background in the field shown is increased too. Furthermore, since Zfh2 overexpressing EBs are larger, the quantitation data needs to be normalized to cell volume; 4) the variation in phospho-4EBP levels on the western blots in Fig. S4A after Rheb overexpression is concerning as Rheb overexpression should give a consistent increase in TOR signaling. To support this it would be helpful to see phospho-4EBP levels in EBs overexpressing Rheb. For these reasons, it is not clear whether Zfh2 activates TOR signaling. Since TOR signaling is an important regulator of protein translation, cell growth and other cellular processes, it is also not terribly surprising that inhibiting TOR signaling blocks Zfh2 induced EB growth (Fig. 5C). Does Zfh2 loss in EBs increase TSC2 levels? (see Kapuria et al., 2012).

8\. The abstract claims that Zfh2 is upstream of MAPK, but there is no data in the manuscript to support this conclusion. MAPK activity has been observed in ISCs (Jiang et al. 2011; Biteau and Jasper, 2011; Liang et al., 2017) but not EBs. The authors should show that MAPK activity is present in differentiating EBs under non-stress conditions. If so, is Zfh2 required for MAPK activation in EBs? Is MAPK (Rolled) required for Zfh2 to promote EB activation and differentiation?

9\. In Fig. 6A, the authors show that overexpression of the activated insulin receptor promotes growth in Zfh2-deficient EBs. But this does not necessarily suggest that insulin signaling acts parallel to Zfh2 in promoting EB differentiation. The loss of TOR from EB blocks its growth and differentiation (similar to Zfh2 loss), but this can be bypassed during regeneration through activation of EGFR signaling (Jiang et al., 2016).

10\. It's not clear what Fig. 2A is showing even after reading the figure legend.

Some general comments:

1\. The title could be more specific and state "progenitor cell activation"

2\. Drosophila should be capitalized and in italics throughout the text

3\. The manuscript would benefit (if known) from more information in the introduction about zfh2 and its regulation/activity in a variety of systems

Reviewer \#2: In "Zfh2 controls cell activation and differentiation in the adult Drosophila intestinal lineage", Villa, Meng and Biteau presents a very nice study of zfh2, a zinc-finger homeodomain transcription factor in regulating the activation of enteroblast (EB) in the adult fly. Under the physiological state, an EB can remain inactivated for up to 14days before differentiating into an enterocyte (EC). The molecular mechanism that confers EB with such long dormancy remains largely unexplored. Here Villa et al depicts zfh2 as a novel player in the determination of intestinal progenitor fate. By carefully tracking the morphological changes in EB coupled to loss- and gain-of-function approaches, the authors demonstrate a requirement for zfh2 for EB growth and activation induced by stress, yet maintaining ectopic zfh2 expression in activated EB blocks EB to EC differentiation, and eventually leads to tumor formation. Furthermore, by studying epistatic interaction between zfh and mTOR and insulin signaling, the authors are able to provide strong evidence that EB growth and morphological changes required for activation are largely separate processes.

While I like this study very much, I do have more questions regarding the data presented in Figure 7. The tumor phenotype of esg\>zfh2 is convincing, striking and intriguing, and I would like to see a bit more characterization. First, are these tumors regionalized? For example, sox21a loss-of-function tumors preferentially grow in the anterior midgut (AMG) of the flies. Secondly, is the tumor formation driven by proliferation from ISCs or elevated endoreplication of the EB cells? It would be a nice control to characterize the tumors further with PH3 staining and BrdU incorporation, while labeling Zhf2 overexpressing cells. Lastly, the high levels of accumulation of Sox21a in the tumors seems counterintuitive based on what we know. It is the current understanding that Sox21a is necessary for EB differentiation into ECs, and sufficient to drive the expression of Pdm1 in the ECs; Loss of Sox21a results in tumor formation, and re-expression of Sox21a specifically in EB cells can prevent this process. The authors here show that overexpression of Zfh2 is sufficient to induce Sox21a expression, yet it correlates with tumor formation. The authors resolve the discrepancy by claiming that zfh2 overexpression tumors and Sox21a loss of function tumors are different: "Sox21a-negative esg-positive early enteroblast in sox21a loss of function and Sox21A-high esg-positive late enteroblast in zfh2 gain of function". This explanation is vague and the language is awkward. If the authors mean that the sox-21a accumulating tumors are late EB cells, is it possible to examine mir8-lacZ expression in this tumors? In addition to attributing the difference to "early" and late" EBs, is it conceivable that Zfh2 overexpression blocks Sox21a activity, and the target of Sox21a is engaged in an ectopic amplification loop of Sox21a expression? It would be interesting to know what happens to Sox21a expression in a zfh1 loss of function clone. Also, what happens to Zfh2 expression in a Sox21a loss of function tumor, and also assess if there is also loss of NRE marker expression in the most apical layer.

Minor Issues:

1\. The authors report an accumulation of EBs bearing small nuclei upon zfh2 knock-down. Based on this observation the authors propose that zfh2 is required for EB endoreplication. The authors should image endoreplication markers in WT and knock-down conditions to strengthen their conclusion.

2\. The authors nicely show elevated p4EBP staining with UAS-zfh2 expression, but the corresponding Western blot in Fig5A and the three panels in FigureS4A are not so convincing. Is it possible to do a pS6K Western in the same condition? By the way, there is a curious observation in the b-actin blot: there are two bands in the UAS Zfh2 and UASRheb, but not in the controls. No I am not asking the authors to resolve the mystery, but if they happen to know why already, it would be nice to share in the figure legend.

3\. The staining with Zfh2 antibody is faint in Figure S1, but am I correct to say that in the non-DSS treated guts, the staining is more diffuse, almost seems cytoplasmic. With DSS treatment, the nuclear staining becomes more prominent and discernable? This seems more obvious to me in the 18hr panel. It is difficult to draw such a conclusion from the figure presentation. It is also unlikely as in previous studies of Zfh2 expression pattern in the wing disc (Terriente et al, 2008), strong nuclear staining of Zfh2 is evident. However, if the authors do concur with my observation, does it imply that Zfh2 is translocated in the nucleus in after stress? Again, this is just my curiosity.

4\. It would be very useful to include scale bars in all the confocal images, and include a clear description of what the arrowheads and stars indicate throughout of figure legend. The authors did so for very few panels. One can deduce what they point to, but the readers should not have to.

5\. Figure 4 panels do not match the figure legend description. Everything is shifted, 4A in the figure is 4B in the legend, 4B is 4C, 4C is 4A.

6\. There is no figure 6G (page 14, line 295). Do the authors mean 6B?

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: No: I did not find an attached spreadsheet of the numerical data or statistics

Reviewer \#2: No:

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: François Leulier
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Author response to Decision Letter 0

23 Oct 2019

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pgen.1008553.r003

Decision Letter 1

Copenhaver

Gregory P.

Editor-in-Chief

Teleman

Aurelio A

Associate Editor

© 2019 Copenhaver, Teleman

2019

Copenhaver, Teleman

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

22 Nov 2019

\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Biteau,

Thank you very much for submitting your Research Article entitled \'Zfh2 controls progenitor cell activation and differentiation in the adult Drosophila intestinal lineage\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. As you will see from the reviewer comments, Reviewer 2 was satisfied with this revised version, whereas Reviewer 1 points out several outstanding issues. We therefore ask you to modify the manuscript as follows, before we can consider your manuscript for acceptance:

1\. remove the p4E-BP western blots (Suppl. Fig 4B) and corresponding text, because they are not convincing. It is not clear which band is the correct band (the one that goes up upon Rheb overexpression may be correct, but this is circular reasoning), the loading between lanes is not equal, total 4E-BP is missing, and overall the signal/noise ratio is poor.

2\. Remove Ras/MAPK signaling from the model in Fig. 8 because you do not seem to have any data that Zfh2 affects Ras/Mapk signaling. The data simply show Ras/MAPK signaling is required for growth, but so is any gene required for cell growth or proliferation (E2F, actin, gadph, etc).

3\. Separate out the Delta staining in Fig. 2A as suggested by Reviewer 1.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Aurelio A Teleman

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors have submitted a revised manuscript that further supports their conclusions that Zfh2 is required and is sufficient to drive EB activation, which includes cellular growth, cell shape change, transient membrane protrusion formation and increased compensatory ISC proliferation. For example, they have provided new data showing that Zfh2 is required for EB activation upon other stresses (e.g. infection, oxidative stress). They have also provided some of the requested controls (e.g. antibody validations) for their experiments and have edited their figures for more clarity. Overall, the data showing Zfh2's role in EB activation are convincing; however, the mechanistic insight into how Zfh2 regulates EB activation/differentiation is disappointedly still weak. The claim that Zfh2 is upstream of TOR and MAPK and parallel to insulin signaling is unfortunately still not well supported.

I've outlined my concerns below:

1\. The authors state that Zfh2 moderately activates TOR signaling but their quantification from their immunostainings and Western blots in Figs. 5A and S4A shows only a 2-fold increase. Furthermore, the increase in phospho-4EBP levels after Rheb overexpression is even less than from Zfh2 overexpression. This is surprising since Rheb is the strongest known positive regulator of TOR signaling. The increases in phospho-4EBP (barely 2-fold) after Rheb overexpression do not reflect the TOR activation shown by previous Rheb overexpression studies (e.g. Saucedo et al., 2003), which show a dramatic increase. As stated in my previous review, the variation of phospho-4EBP levels on the Western blots in Figure S4B after Rheb overexpression is concerning as Rheb overexpression should consistently increase TOR activity and thus phosphor-4EBP levels. Reviewer 2 also expressed concerns about these Western blots. Even if TOR activity was increased 2-fold by Zfh2, it's not clear whether this amount of TOR activity can effect EB activation. Additionally, the phospho-4EBP staining in Figure S4A is not consistent with the Western blots in S4B. The phospho-4EBP levels in Fig S4A do not surprisingly increase in all cells (ISC and EB pairs) in the field after Rheb overexpression for 3 days. If there are fewer progenitors positive for TOR activation per midgut and Rheb overexpression doesn't increase TOR signaling as much as Zfh2 overexpression, then why does the Western blot quantification (Fig. S4B) show that Rheb overexpression increases TOR activity more than Zfh2 overexpression? Also to note, the WB quantification does not seem to match what is observed in the provided Western blots. Altogether, this data does not convincingly show that Zfh2 moderately increases TOR activity and whether this activation is effective for EB activation. Lastly, as mentioned in my previous review, the requirement for TOR (an essential regulator of many cellular processes including protein translation) for Zfh2 to promote EB growth is not surprising.

2\. The data suggest that InR, MAPK and TOR signaling are sufficient to promote EB growth and that insulin signaling can also promote non-autonomous ISC proliferation as published by Choi et al., 2011. The data also suggest that Ras and TOR signaling are required for Zfh2-mediated EB growth. However, the authors do not identify how Zfh2 promotes cell shape change, protrusion formation and non-autonomous ISC proliferation (which they show does not require insulin signaling). Additionally, the data suggest that insulin, Ras and Rheb signaling are not sufficient to drive full EB activation. The manuscript is about EB activation by Zfh2, which they have defined to include cellular growth, cell shape change and protrusion formation. Although Ras and Tor signaling seem to be required for Zfh2 induced EB growth, it's not convincing from the data provided if they are required downstream or in parallel to Zfh2 activity. Convincing evidence that Zfh2 activity can activate Ras and TOR signaling and including parallel genetic experiments with controls that determine that Tor and Ras are downstream (and not parallel) to Zfh2 would strengthen the manuscript.

3\. The authors suggest that E-cadherin may be affected by Zfh2 activity in EBs. Choi et al., 2011 suggest that insulin signaling in EBs downregulates E-cadherin level between the ISC and EB, thus triggering ISC proliferation. Thus, testing whether Zfh2 is required for E-caherin downregulation could support its role in non-autonomous induction of ISC proliferation, possibly through insulin signaling.

4\. Their data suggests that Zfh2 is required in EBs that have received a Notch signal (GBE+) for their growth and differentiation. Whether TOR is strongly activated by Zfh2 is not clear from the provided data and the data also doesn't provide a mechanism by which TOR is activated by Zfh2. I suggested in my previous review that the authors could check whether Zfh2 loss results in increased TSC2 levels. It has been reported that TSC2 is downregulated in EBs by a Notch signal (Kapuria et al., 2012), but how this occurs is not known.

Minor comments:

1\. The Delta staining in Fig. 2A is not visible. I suggest separating the channels so that the Delta staining can be clearly shown. If the purpose for this panel is to show how each cell-type was identified for quantification, the control could be included in the main figure and the other genotypes could be placed into a supplementary figure.

2\. The data supports that Zfh2 is important for absorptive lineage-progenitor activation. Thus, the title of the manuscript should include the words "absorptive lineage progenitor cell activation." I would also discuss that EE-progenitors may also require activation.

Reviewer \#2: The authors answer to my previous comments in a satisfactory way and as a result the manuscript has improved. I feel the story is now of sufficient interest and quality to be published.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: François Leulier

10.1371/journal.pgen.1008553.r004
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Dear Dr Biteau,

We are pleased to inform you that your manuscript entitled \"Zfh2 controls progenitor cell activation and differentiation in the adult Drosophila intestinal absorptive lineage\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Aurelio A Teleman

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-00930R2>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.
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